F13a/Coagulation Factor XIII A Chain | E21-880

F13a/Coagulation Factor XIII A Chain | E21-880 | Gentaur UK, US & Europe Distribution

Short Description: Recombinant Human Coagulation Factor XIII A Chain is produced by our Mammalian expression system and the target gene encoding Gly39-Met732 is expressed with a 6His tag at the C-terminus.

Shipping: Dry ice/ice packs

Formulation: Supplied as a 0.2 m filtered solution of 50 mM NaCl, 5% Sucrose, 1% Tween 20 (v/v) , 0.3% Histidine (w/v) , pH8.0.

Storage: Store at < -20C, stable for 6 months after receipt.
Please minimize freeze-thaw cycles.

Reconstitution: N/A

Purity: Greater than 95% as determined by reducing SDS-PAGE.

Endotoxin: Less than 0.1 ng/g (1 IEU/g) as determined by LAL test.

Background: Coagulation factor XIII is the last zymogen to become activated in the blood coagulation cascade. Plasma factor XIII is a heterotetramer composed of 2 A subunits and 2 B subunits. The A subunits have catalytic function, and the B subunits do not have enzymatic activity and may serve as plasma carrier molecules. Platelet factor XIII is composed of just 2 A subunits, which are identical to those of plasma origin. Upon cleavage of the activation peptide by thrombin and in the presence of calcium ion, the plasma factor XIII dissociates its B subunits and yields the same active enzyme, factor XIIIa, as platelet factor XIII. This enzyme acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine crosslinking between fibrin molecules, thus stabilizing the fibrin clot. Factor XIII deficiency is classified into two categories: type I deficiency, characterized by the lack of both the A and B subunits; and type II deficiency, characterized by the lack of the A subunit alone. These defects can result in a lifelong bleeding tendency, defective wound healing, and habitual abortion.

Species: Human

Expression System: Human Cells